Zhe Li

Introduction: Cervical cancer is the fourth most commonly diagnosed malignancy among women globally, with HPV infection being the primary cause. Large-scale HPV screening is crucial for early detection, as appropriate intervention in HPV-positive individuals can significantly reduce cervical cancer incidence and mortality.Methods: Data were extracted from the Shenzhen Maternal and Child Health Management Information System, covering 18,667 HPV infection and cervical cancer screening instances among 15,850 women from January 1, 2020, to December 31, 2023. HPV prevalence and corresponding 95% confidence intervals (CIs) were calculated using SPSS (version 27.0).Results: From January 2020 to December 2023, the overall HPV infection rate was 12.39%, with a notably higher rate of 23.38% in women over 60 years. The hr-HPV infection rate was 12.99%, with HPV types 52, 58, 16, 51, and 68 being the most common. Among women with positive ThinPrep Cytologic Test (TCT) results, the hr-HPV infection rate was 53.37%. In women with positive cervical histopathology, the hr-HPV infection rate reached 95.95%. With increased HPV vaccination doses, the infection rates of HPV16, 18, 52, 58, 51, 31, 33, 45, 6, and 11 decreased among individuals under 30, but increased in those over 45.Discussion: These findings suggest that enhancing HPV vaccination coverage and cervical cancer screening, especially for women over 45, are effective strategies to reduce hr-HPV infection rates and cervical cancer incidence in this region.

Postpartum maternal depression and socioeconomic factors are established risk factors for the mental health of offspring. It has been consistently unclear as to whether female or male offspring are more vulnerable to the effects of postpartum maternal depression at different stages of the child’s life course. To determine whether the characteristics of postpartum maternal depression with a history of prenatal depression influence sex differences in offspring internalizing symptoms across childhood and adolescence, socioeconomic factors should be considered. We systematically searched PubMed, Embase, PsycINFO, CNKI, and SinoMed databases from inception to November 28, 2023, and selected longitudinal cohort studies that quantified sex differences in internalizing symptoms of children and adolescents. Pooled standardized mean differences (SMDs) were calculated using random-effects models. ROBINS-E tool was used to rate the quality of evidence. Twenty-eight studies were eligible between 1997 and 2023, including 24,022 mother–child dyads. Sex-difference trajectories of offspring internalizing symptoms were identified after exposure to postpartum maternal depression, ranging from a lack of significant sex differences in childhood to a higher prevalence observed among girls than boys in adolescence (SMD, 0.25, 95% CI, 0.13–0.38). Economic income and maternal education affected the associations between the magnitude and concurrent recurrence of postpartum depression and significant sex differences in adolescent internalizing symptoms, respectively. After adjusting for socioeconomic factors, early nonconcurrent recurrence of postpartum depression was associated with greater odds of internalizing symptoms among adolescent girls than among boys (β = 0.03, 95% CI, 0.01–0.06); however, there was no statistical significance after adjusting for prenatal depression. Socioeconomic factors differentially impacted the association between postpartum maternal depression and significant sex differences in adolescent internalizing symptoms. Independent of socioeconomic factors and prenatal depression, postpartum maternal depression was not associated with significant sex differences in adolescent internalizing symptoms. Therefore, the significant sex effects of postpartum maternal depression are more likely due to complex interactions between maternal depression and the intrauterine and postpartum environments that shape offspring sex-difference trajectories, with consequences occurring for later internalizing symptoms in adolescence. PROSPERO, CRD42022301445.

Abnormal uterine bleeding (AUB) is a common gynecological issue during reproductive years. Researches on how dietary diversity and patterns influence AUB in Chinese university students are limited, with some studies not clearly defining irregular menstruation. This research investigated the incidence of AUB according to the International Federation of Gynecology and Obstetrics criteria and sought to identify preventative factors via online questionnaires. Food intake was assessed via factor analysis. This study analyzed the relationships among the dietary diversity score (DDS), dietary patterns, and AUB via univariate and multivariate binary logistic regression models and generalized additive models. The sample consisted of 698 students, with 434 (62.2%) having experienced AUB. Among them, 87 (20.05%) reported abnormal frequency, 250 (57.60%) reported irregular menstrual cycle, 41 (9.45%) reported prolonged duration, and 268 (61.75%) reported abnormal flow volume. A 1-unit increase in the DDS was linked to a 22% lower risk of AUB (odds ratio 0.78, 95% CI: 0.67, 0.90). A high DDS (≥ 6) was consistently associated with a lower risk of AUB across all the models. Using a two-piecewise linear regression model and recursive algorithm, a nonlinear, reverse L-shaped relationship was identified between the “low fat plant-based” dietary pattern factor score (FAC4) and AUB, with an inflection point of 1.45. Before this point, FAC4 had a protective effect on AUB (odds ratio 0.42, 95% CI: 0.21, 0.84). Our study underscores the importance of a varied diet as a preventive measure for AUB, utilizing a DDS to quantify the relationship between dietary diversity and AUB. According to our findings, higher dietary diversity and moderate adherence to a “low fat plant-based” dietary pattern may be significant protective factors against AUB in university students.

Ovarian cancer (OV) ranks among the deadliest gynecological cancer, known for its high risk of relapse and metastasis, and a general resistance to conventional platinum‐based chemotherapy. Selenoprotein I (SELENOI) is a crucial mediator implicated in human hereditary spastic paraplegia. However, its role in human tumors remains poorly elucidated. Here, we comprehensively analyzed SELENOI expression patterns, functions, and clinical implications across various malignancies through the integration of bulk transcriptomics, cancer databases, and in vitro and in vivo experiments. Pan‐cancer analysis indicated upregulated SELENOI expression across various cancers, correlating with augmented malignancy, suppressed tumor immunity and poor prognosis. Knockdown of SELENOI caused G0/G1‐phase cell cycle arrest and diminished aggressive cancer phenotypes in OV cells. Moreover, SELENOI inhibition augments ferroptosis and reverses the cisplatin resistance in OV cells by modulating Akt phosphorylation. Conversely, overexpression of SELENOI in OV cells enhanced therapeutic sensitivity to cisplatin by upregulating Akt phosphorylation. Importantly, in vivo studies demonstrated that SELENOI inhibition suppressed ovarian tumor growth and enhanced cisplatin's anticancer effects. These findings highlight the significant role of SELENOI in OV by modulating ferroptosis and chemotherapy resistance. Targeting SELENOI represents a promising therapeutic approach to promote the efficacy of platinum‐based chemotherapy in OV, particularly in cases of resistance.

PU.1, a transcription factor member of the E26 transformation-specific family, affects the function of a variety of immune cells in several physiological and pathological conditions. Previous studies studying the role of PU.1 in pathological conditions have mainly focused on immune system-related cancers, and a series of articles have confirmed that PU.1 mutation can induce a variety of immune cell-related malignancies. The underlying mechanism has also been extensively validated. However, the role of PU.1 in other major immune system-related diseases, namely, systemic autoimmune diseases, is still unclear. It was only in recent years that researchers began to gradually realize that PU.1 also played an important role in a variety of autoimmune diseases, such as rheumatoid arthritis (RA), experimental autoimmune encephalomyelitis (EAE) and systemic lupus erythematosus (SLE). This review article summarizes the findings of recent studies that investigated the role of PU.1 in various autoimmune diseases and the related underlying mechanisms. Furthermore, it presents new ideas and provides insight into the role of PU.1 as a potential treatment target for autoimmune diseases and highlights existing research problems and future research directions in related fields.

The tumor‐suppressor role of long noncoding RNA (lncRNA) growth arrest‐specific transcript 5 (GAS5) has been proven in various types of cancer. However, the specific function of GAS5 in tumor‐associated macrophages (TAMs) of endometrial cancer (EC) is elusive. Quantitative PCR results showed that GAS5 expression decreased in EC tissues and primary TAMs from EC tumors. Tumor‐associated macrophage infiltration was significantly positively associated with the developmental stage of EC. Direct coculture of GAS5‐overexpressing TAMs and EC cells showed that GAS5 enhanced phagocytosis, antigen presentation, and activation of cytotoxic T cells, and repressed “Don’t eat me” signals between TAMs and EC cells. Tumor formation in immunodeficient mice showed that GAS5‐overexpressing macrophages could repress EC formation in vivo. GAS5 promoted M1 polarization by activating the microRNA‐21– phosphatase and tensin homolog (PTEN)–AKT signaling pathway and directly repressing the nuclear accumulation and phosphorylation of oncogenic yes‐associated protein 1 (YAP1) in TAMs. GAS5 inhibited the development of EC from both innate and adaptive immunity by transforming TAMs from a protumor to an antitumor phenotype. These antitumor effects of GAS5 on TAMs were mediated by the activation of the miR‐21‐PTEN‐AKT pathway and inhibition of YAP1.

The pathogenesis of ovarian and endometrial cancers is closely associated with estrogen-related pathways. These estrogen-dependent tumors seriously threaten the health and quality of life in women. Noncoding RNAs (ncRNAs) are defined as RNAs that do not encode proteins, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), both of which have been reported in estrogen-dependent female reproductive system tumors. This review systematically summarizes the role of ncRNAs in estrogen-dependent tumors and common patterns of regulatory mechanisms to explore their future research directions in tumor diagnosis, treatment, and prognosis. This may provide new ideas for the potential application of ncRNAs in estrogen-dependent female reproductive system tumors.

Coronavirus disease 2019 (COVID‐19) is a novel type of highly contagious pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Despite the strong efforts taken to control the epidemic, hundreds of thousands of people were infected worldwide by Mar. 11^th, and was characterized as a pandemic by World Health Organization. Pregnant women are more susceptible to the virus due to immune and anatomic alteration, though hospital visits may increase the chance of infection, the lack of medical care during pregnancy may do more harm. Hence, a well‐managed system that allows pregnant women to access maternal health care with minimum exposure risk is desired during the outbreak. Here, we present the managing processes of three pregnant women that had a fever during hospitalization at gynecology or obstetrics department, then further summarize and demonstrate our maternal health care management strategies including antenatal care planning, patient triage based on risk level, admission control, and measures counteracting emergencies and newly discovered high risk cases at in‐patient department. In the meantime, we will explain the alterations we have done throughout different stages of the epidemic, and also review relative articles in both Chinese and English to compare our strategies with those of other areas. Although tens of COVID‐19 cases were confirmed in our hospital, no nosocomial infection has occurred and none of the pregnant woman registered in our hospital was reported to be infected.